Trial shows aducanumab removes amyloid plaque in Alzheimer's patients

Amyloid plaque in the brain has been shown to be a leading factor in the development of Alzheimer’s. Clinical testing explored if the monoclonal antibody aducanumab could stop plaque buildup.

The Phase 1b PRIME clinical trial on the effectiveness of aducanumab has come to an end after a year of evaluation. The results show that it can remove plaque from the brain in both a dose- and time-dependent manner. Using positron emission tomography (PET) to show the brain, researchers noted a drop in the level of amyloid plaque. This discovery lead to less of a cognitive decline in patients and offers a great deal of support the hypotheses that amyloid build of is a key factor in patient decline in health due to Alzheimer’s.

"These results potentially represent a major step forward in the fight against Alzheimer's disease; the magnitudes of the effects as well as their time- and dose-dependency are truly intriguing," said Professor Roger M Nitsch, MD, Co-Founder and President of Neurimmune. "Aducanumab also demonstrates a proof-of-concept for our RTM technology platform. It gives us further evidence that our approach is working and provides promise for many of the other drugs we are developing using this technology"